Trusted Resources: News & Meetings
Latest announcements and gatherings
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Market Research Report – Global Clinical Trials Review, H2, 2021 – ResearchAndMarkets.com
The “Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) – Global Clinical Trials Review, H2, 2021” clinical trials has been added to ResearchAndMarkets.com’s offering. The clinical trial report provides an overview of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Clinical trials scenario. This report provides top line data relating to the clinical trials on Mucopolysaccharidosis I (MPS I) (Hurler Syndrome).
Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
BookmarkRelated Content
-
Steve HollandSteve Holland, CPA is the proud father o...
-
Progression of Cardiovascular Manifestations in Adults and Children With Mucopolysaccharidoses With and Without Enzy...Cardiovascular involvement is among the ...
-
Corneal Cloudiness: A Presenting Feature of Mucopolysaccharidosis Type IA 10-y-old ‘short-statured’ male pre...
-
UPMC Children’s Hospital of Pittsburgh – Center for Rare Disease TherapyHurler syndrome (mucopolysaccharidosis t...
-
Hurler Syndrome Treatment Market Research Prophesied to Grow at a Faster Pace By 2026This Hurler Syndrome Treatment market re...
-
Advances in Approaches to Care and Monitoring of MPS Diseasehttps://www.youtube.com/watch?v=JZSVzeiX...
-
Proposal of An Algorithm to Early Detect Attenuated Type I Mucopolysaccharidosis (MPS IA) Among Children With Growth...Diagnostic delay is common in attenuated...
Powered by
